Quantcast

Latest Tumor antigen Stories

2011-02-09 06:00:00

CAMBRIDGE, Mass., Feb. 9, 2011 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by normalizing the immune response, presented results from preclinical studies with TRX518, a first-in-class immunomodulatory agent for the treatment of cancer. TRX518 is a monoclonal antibody reactive with the glucocorticoid-induced tumor necrosis factor receptor (GITR) and is designed to enhance the immune system's anti-tumor...

2010-08-09 10:10:00

GAITHERSBURG, Md., Aug. 9 /PRNewswire/ -- Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, announced today that it has received a National Institutes of Health (NIH) Small Business Innovation Research grant (SBIR) for a program on "Clinical Vector for TCR Immunotherapy Targeted to Melanoma". In this program, Lentigen will collaborate with Dr. Michael Nishimura, Professor of Surgery, at the Medical...

2010-06-15 15:47:07

Combined targeted therapy against the BRAF/MAPK pathway with immunotherapy shows promise as a new therapeutic approach for the treatment of melanoma, according to results of a preclinical study published in Cancer Research, a journal of the American Association for Cancer Research. "Our results provide preclinical evidence for the rational combination of BRAF-targeted therapy and immunotherapy in the treatment of this most dangerous type of skin cancer," said lead researcher Jennifer A....

f0c74c1257ccc9e4e57b8b862004281c1
2010-03-25 14:35:24

EPFL study reveals importance of relation between the lymphatic system and tumors A new mechanism explaining how tumors escape the body's natural immune surveillance has recently been discovered at EPFL (Ecole Polytechnique F©d©rale de Lausanne) in Switzerland. The study shows how tumors can create a tolerant microenviroment and avoid attack by the immune system by mimicking key features of lymph nodes. The discovery, published in Science and in Science Express, online March 25,...

2010-03-03 11:00:00

DES PLAINES, Ill., March 3 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) announced today that it has entered into an agreement with GlaxoSmithKline (GSK) to develop a molecular diagnostic test intended for use as an aid in selecting patients who may benefit from a skin cancer treatment in development by GSK. GSK's MAGE-A3 ASCI (Antigen-Specific Cancer Immunotherapeutic) candidate is currently being evaluated as an adjuvant treatment in melanoma biopsy specimens in the Phase III clinical...

86fb375d9b7810c2b867e5e09ded0a2f1
2009-11-30 14:17:15

The University of Navarra Hospital has launched a series of clinical trials in order to assess the efficacy of an immunotherapy treatment. This approach involves the application of personalized vaccines "”produced from healthy and tumor cells from the patient him or herself"” and designed to combat glioblastomas, one of the most aggressive and frequent malignant tumors. The new therapy is administered to participating patients combined with the standard, first-line treatment...

2009-10-29 15:43:05

Helper T cell's effect raises possibility of cellular therapy, vaccine development A specific type of T helper cell awakens the immune system to the stealthy threat of cancer and triggers an attack of killer T cells custom-made to destroy the tumors, scientists from The University of Texas M. D. Anderson Cancer Center report in the early online edition of the journal Immunity. The role of Th17, one of only four known types of T helper cell, opens a possible avenue for overcoming cancer's...

2009-10-21 13:38:50

It was once thought that the two communities of cells within a cancerous breast tumor "“ fast-growing malignant cells and the normal cells that surround them "“ existed independently, without interaction. Then evidence emerged indicating that the normal-looking cells encouraged cells within the tumor to become malignant, but how the one community influenced the other wasn't known. A new study led by Ohio State University cancer researchers published in the Oct. 22 issue of Nature...

2009-07-13 11:26:00

DES PLAINES, Ill., July 13 /PRNewswire-FirstCall/ -- Abbott announced today that it has entered into an agreement with GlaxoSmithKline (GSK) to develop an automated molecular diagnostic test, based on polymerase chain reaction (PCR) technology, intended to screen non-small cell lung cancer (NSCLC) tumors for expression of the MAGE-A3 antigen. GSK's MAGE-A3 ASCI (Antigen Specific Cancer Immunotherapy) candidate is currently being evaluated as an adjuvant treatment in resected NSCLC in the...

2009-07-01 07:15:51

Researchers have identified a protein released by dying brain tumor cells that provides an effective way to gauge the effectiveness of a novel gene therapy treatment for brain cancer. The finding paves the way for a Phase 1 clinical trial expected to begin in late 2009. The two-pronged gene therapy was devised by scientists at the Cedars-Sinai Board of Governors Gene Therapeutics Research Institute.  It uses a harmless, genetically engineered virus to deliver a combination of...


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related